Opakalim Clinical Hold Enters Third Month... When Will SK Biopharm License the 'KRW 1 Trillion Drug'?
Biohaven Has Yet to Submit Additional Data
More Than a Month Behind the Target Timeline
Key Condition for Closing Completed Last Month
"The Two Companies Will Continue to Work Closely Together"
The U.S. clinical hold on Opakalim, a novel epilepsy drug candidate that SK Biopharm agreed to license for up to KRW 1.1 trillion, has continued for more than two months. The company’s original target of lifting the hold in “October or November” now appears increasingly uncertain. With the timeline expected to slip, attention is also turning to the payment of the upfront fee and the closing process for the deal with U.S. developer Biohaven.
SK Biopharm CEO Lee Donghoon gives a presentation at a press conference on the technology licensing of "Opakalim" held on August 26. SK Biopharm
View original imageAccording to industry sources on November 17, Biohaven has yet to submit the additional nonclinical data requested by the U.S. Food and Drug Administration (FDA). The original plan was to complete the submission around September or October and lift the clinical hold by November at the latest, but the timeline has slipped considerably. On September 4, the FDA notified Biohaven of a partial clinical hold and requested additional information, saying there was insufficient evidence to assess the risk to humans from a specific metabolite of Opakalim observed in a rodent nonclinical study. Even after the data are submitted, the FDA review could take up to a month, making it difficult to expect the hold to be lifted this month.
SK Biopharm sees Opakalim as a next-generation pipeline candidate that could follow its blockbuster epilepsy drug Xcopri (generic name: cenobamate). In August, the company signed a licensing agreement with Biohaven worth up to $795 million (approximately KRW 1.0996 trillion), including an upfront payment of $400 million (approximately KRW 553.2 billion). This is the largest deal to date for a domestic pharmaceutical or biotech company licensing a drug candidate. SK Biopharm aimed to secure a product expected to be suitable for a broad range of patients, given its relatively low incidence of central nervous system side effects, and develop it into a future growth driver.
However, the deal between the two companies has also been put on hold, after the partial clinical hold was imposed just nine days after the agreement was signed. According to SK Biopharm’s quarterly report filed the previous day, the upfront payment had not yet been made as of the end of September. Under the agreement, $350 million of the $400 million upfront payment is due upon closing, while the remaining $50 million is payable one year after closing. Given the clinical uncertainties, SK Biopharm plans to make the upfront payment after the hold is lifted. An SK Biopharm official said, “The two companies are discussing in detail a payment arrangement under which the upfront fee will be paid after the clinical hold is lifted.”
The key issue is the closing conditions set out in the agreement between the two companies. According to the agreement Biohaven disclosed to the U.S. Securities and Exchange Commission (SEC), the waiting period for U.S. antitrust review, a key condition precedent to closing, ended on October 28. This means that the key conditions for closing have effectively been met and that, in principle, Biohaven could demand that the deal close and the upfront payment be made even before the hold is lifted. The agreement also states that closing may be delayed in the event of a “material adverse effect” (MAE). However, some analysts say it would be difficult to argue that the current hold qualifies, given that SK Biopharm has publicly stated it was aware of the toxicology finding at issue before signing the agreement. Biohaven was in a state of capital impairment at the end of the third quarter, with liabilities exceeding assets, making the upfront payment financially significant for the company as well.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
SK Biopharm plans to focus all its resources on the topline results from the Phase 2/3 RISE3 trial, which are expected to be released by the end of the year. Since the hold stems from a nonclinical metabolite issue rather than efficacy, the RISE3 results are expected to be the first test of Opakalim’s value. An SK Biopharm official said, “We also view the topline results expected by year-end as our most important event,” adding, “Separately, the two companies will continue to work closely together on when and how to lift the clinical hold and close the deal.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.